The safety and efficacy of the use of vasopressin in sepsis and septic shock

Expert Opinion on Drug Safety

Volumn 4, Issue 6, 2005, Pages 1027-1039

  Wilson, Stephen J ^a   Mehta, Saurabh S ^a   Bellamy, Mark C ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Safety; Sepsis; Septic shock; Terlipressin; Vasopressin; Vasopressor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; CARBAMAZEPINE; CATECHOLAMINE; CHLORPROMAZINE; DESMOPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; MILRINONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TERLIPRESSIN; TRICYCLIC ANTIDEPRESSANT AGENT; VASOPRESSIN;

ABDOMINAL CRAMP; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONVULSION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HEADACHE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NAUSEA; PATHOGENESIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZATION; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN MANIFESTATION; SKIN NECROSIS; STOMACH PAIN; VOMITING; WATER RETENTION; WEIGHT GAIN;

CLINICAL TRIALS; DRUG COSTS; HEMOSTATICS; HUMANS; SEPSIS; SHOCK, SEPTIC; VASOPRESSINS;

EID: 27944478678     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.6.1027     Document Type: Review

References (73)

1. AMERICAN COLLEGE OF CHEST PHYSICIANS/SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. (1992) 20:864-874.
2. DELLINGER R, CARLET J, MASUR H et al.: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. (2004) 32:858-871.
3. MEIER-HELLMAN A, VLASAKOV K: Management of sepsis. European Society of Anaesthesiology, Euroanaesthesia 2004, Lisbon, Portugal (2004) 12RC2.
4. HOTCHKISS R, KARL I: The pathophysiology and treatment of sepsis. N. Engl. J. Med. (2003) 348:138-150.
5. OLIVER G, SCHAEFER AE: On the physiological action of extract of pituitary body and certain other glandular organs. J. Physiol. (1895) 18:277-279.
6. HADENGUE A, GADANO A, MOREAU R et al.: Beneficial effects of the 2-day administration of Terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol. (1998) 29:565-570.
7. RESTUCCIA T, ORTEGA R, GUEVARA M et al.: Effects of treatment of hepatorenal syndrome before transplantation on post-transplantation outcome. A case control study. J. Hepatol. (2004) 40:140-146.
8. IANNOU G, DOUST J, ROCKEY D: Systematic review: Terlipressin for acute oesophageal variceal haemorrhage. Aliment. Pharmacol. Ther. (2003) 17:53-64.
9. MOREAU R, ASSELAH T, CONDAT B et al.: Comparison of the effect of Terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites being treated by paracentesis: a randomised pilot study. Gut (2002) 50:90-94.
10. WENZEL V, KRISMER AC, ARNTZ HR et al.: A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N. Engl. J. Med. (2004) 350:105-113.
11. HOGG K, MAHU R: Vasopressin or adrenaline in cardiac resuscitation. Emerg. Med. J. (2003) 20:467.
12. AUNG K, HTAY T: Visopressin for Cardiac Arrest: A Systematic Review and Meta-analysis. Arch. Intern. Med. (2005) 165:17-24.
13. MORELLI A, et al.: Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics. Anesthesiology (2005) 102:12-9.
14. DUNN FL, BRENNAN TJ, NELSON AE, ROBERTSON GL: The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J. Clin. Invest. (1973) 52:3212-3219.
15. WADE CE, KEIL LC, RAMSAY DJ: Role of volume and osmolality in the control of plasma vasopressin in dehydrated dogs. Neuroendocrinology (1983) 37:349-343.
16. COWLEY AW Jr, CUSHMAN WC, QUILLEN EW Jr, SKELTON MM, LANGFORD HG: Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension (1981) 3:I93-I100.
17. BERL T, ROBERTSON GL: Pathophysiology of water metabolism. In: Brenner and Rector's The Kidney. Brenner BM (Ed), Saunders, Philadelphia (2000):866-924.
18. ROBINSON AG, VERBALIS JG: Posterior pituitary gland. In: Williams Textbook of Endocrinology. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (Eds), Saunders, Philadelphia (2003):281-330.
19. ROBERTSON GL, SHELTON RL, ATHAR S: The osmoregulation of vasopressin. Kidney Int. (1976) 10:25-37.
20. BIRNBAUMER M: Vasopressin receptors. Trends Endocrinol. Metab. (2000) 11:406-410.
21. MANNUCCI PM, ABERG M, NILSSON IM, ROBERTSON B: Mechanism of plasminogen activator and Factor VIII increase after vasoactive drugs. Br. J. Haematol. (1975) 30:81-93.
22. RICHARDSON DW, ROBINSON AG: Desmopressin. Ann. Intern. Med. (1985) 103:228-239.
23. SUGIMOTO T, SAITO M, MOCHIZUKI S, WATANABE Y, HASHIMOTO S, KAWASHIMA H: Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J. Biol. Chem. (1994) 269:27088-27092.
24. THIBONNIER M, PRESTON J, DULIN N, WILKINS P, BERTI-MATTERA L, MATTERA R: The human V3 pituitary vasopressin receptor. Ligand binding profile and density-dependent signalling pathways. Endocrinology (1997) 138:4109-4122.
25. THIBONNIER M, CONORTY D, PRESTON J, PLEISNICHER C, DWEIK R, ERZURUM S: Human vascular endothelial cells express oxytocin receptors. Endocrinology (1999) 140:1301-1309.
26. WILSON M, BRACKETT D, TOMPKINS P, BENJAMIN B, ARCHER L, HINSHAW L: Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv. Shock Res. (1981) 6:15-26.
27. BRACKETT D, SCHAEFER C TOMPKINS P, FAGRAEUS L, PETERS L, WILSON M: Evaluation of cardiac output, total peripheral resistance and plasma concentrations of vasopressin in the conscious, unrestrained rat during endoroxemia. Circ. Shock (1985) 17:273-284.
28. KASTING N, MAZUREK M, MARTIN J: Endotoxin increases vasopressin release independently of known physiological stimuli. Am. J. Phyisol. (1985) 248:E420-E424.
29. MASTORAKOS G, WEBER J, MAGIAKOU M, GUNN H, CHROUSOS G: Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J. Clin. Endocrinol. Metab. (1994) 79:934-939.
30. CHIKANZA I, PETROU P, CHROUSOS G: Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann. NY Acad. Sci. (2000) 917:825-834.
31. ZELAZOWSKI P, PATCHEV V, ZELAZOWSKA E, CHROUSOS G, GOLD P, STERNBERG E: Release of hypothalamic corticotrophin releasing hormone and arginine-vasopressin by interleukin 1 beta and alpha MSH: studies in rats with different susceptibilities to inflammatory disease. Brain Res. (1993) 631:22-26.
32. SHARSHAR T, BLANCHFORD A, PAILLARD M, RAPHAEL J, GAJDOS P, ANNANE D: Circulating vasopressin levels in septic shock. Crit. Care Med. (2003) 31:1752-1758.
33. LANDRY D, LEVIN H, GALLANT E et al.: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation (1997) 95:1122-1125.
34. BUCHER M, HOBBHAHN J, TAEGER K, KURTZ A: Cytokine mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am. J. Physiol. Regul Integr Comp Physiol (2002) 282:R979-R984.
35. KUSANO E, TIAN S, UMINO T et al.: Arginine vasopressin inhibits interleukin 1 beta stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J. Hypertens. (1997) 15:627-632.
36. WAKATSUKI T, NAKAYA Y, INOUE I: Vasopressin modulates K+-channel activities of cultured smooth muscle cells from porcine coronary artery. Am. J. Physiol. (1992) 263:H491-H496.
37. MÜLLNER M, URBANEK B, HAVEL C, LOSERT H, WAECHTER F, GAMPER G: Vasopressors for shock. Cochrane Database Syst. Rev. (2004) Issue 3. CD003709.pub2.
38. BEALE R, HOLLENBERG S, VINCENT J, PARILLO J: Vasopressor and inotropic support in septic shock: an evidence based review. Crit. Care Med. (2004) 32:S455-S465.
39. CHEN J, CULLINANE S, SPANIER T et al.: Vasopressor deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation (1999) 100:11244-11246.
40. BOCCARA G, OUATTARA A, GODET G et al.: Terlipressin versus Norepinephrine to correct refractory arterial hypotension after general anaesthesia in patients chronically treated with rennin angiotensin system inhibitors. Anesthesiology (2003) 98:1338-1344.
41. EYRAUD D, BRABANT S, NATHALIE D et al.: The treatment of intraoperative refractory hypotension with Terlipressin in patients chronically treated with an antagonist of the renin angiotensin system. Anesth. Analg. (1999) 88:980-984.
42. ARGENZIANO M, CHOUDHRI A, OZ M, ROSE E, SMITH C, LANDRY D: A prospective randomised trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation (1997) 96:II286-II290.
43. ARGENZIANO M, CHEN J, CHOUDHRI A et al.: Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac. Cardiovasc. Surg. (1998) 116:973-980.
44. GOLD J, CULLINANE S, CHEN J et al.: Vasopressin in the treatment of milrinone induced hypotension in severe heart failure. Am. J. Cardiol. (2000) 85:506-588, A11.
45. ROSENZWEIG E, STARC T, CHEN J et al.: Intravenous arginine vasopressin in children with vasodilatory shock after cardiac surgery. Circulation (1999) 100:II182-II186.
46. MALAY M, ASHTON R, LANDRY D et al.: Low dose vasopressin in the treatment of vasodilatory septic shock. J. Trauma (1999) 47:699-703.
47. TSUNEYOSHI I, YAMADA H, KAKIHANA Y et al.: Hemodynamic and metabolic effects of low dose vasopressin infusions in vasodilatory septic shock. Crit. Care Med. (2001) 29:487-493.
48. PATEL B, CHITTOCK D, RUSSELL J, WALLEY K: Beneficial effects of short term vasopressin infusion during severe septic shock. Anesthesiol. (2002) 96:576-582.
49. VINCENT J, DE MENDONCA A, CANTRAINE F et al.: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentre, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit. Care Med. (1998) 26:1793-1800.
50. MUTLU G, FACTOR P: Role of vasopressin in the management of septic shock. Intensive Care Med. (2004) 30:1276-1291.
51. VAN HAREN F, ROZENDAAL F, VAN DER HOEVEN J: The effect of vasopressin on gastric perfusion in catecholamine dependent patients in septic shock. Chest (2003) 124:2256-2260.
52. HAMU Y, KANMURA Y, TSUNEYOSHI I et al.: The effects of vasopressin on endotoxin-induced attenuation of contractile responses in human gastroepiploic arteries in vitro. Anesth. Analg. (1999) 88:542-548.
53. VARGA C, PAVO I, LAMARQUE D et al.: Endogenous vasopressin increases acute endotoxin shock-provoked gastrointestinal mucosal injury in the rat. Eur. J. Pharmacol. (1998) 352:257-261.
54. DUNSER M, MAYR A, ULMER H et al.: Arginine vasopressin in advanced vasodilatory shock. A prospective, randomised, controlled study. Circulation (2003) 107:2313-2319.
55. LANDRY D, LEVIN H, GALLANT E: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit. Care Med. (1997) 25:1279-1282.
56. O'BRIEN A, CLAPP L, SINGER M: Terlipressin for Norepinephrine resistant septic shock. Lancet (2002) 359:1209-1210.
57. OBRITSCH M, JUNG R, FISH D, MACLAREN R: Effects of low dose vasopressin infusion in patients with septic shock. Ann. Pharmacother. (2004) 38:1117-1122.
58. HOLMES C, WALLEY K, CHITTOCK D, LEHMAN T, RUSSELL J: The effects of vasopressin on haemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. (2001) 27:1416-1421.
59. MORELLI A, ROCCO M, CONTI G et al.: Effects of Terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med. (2004) 30:597-604.
60. DUNSER M, MAYR A, TUR A et al.: Ischaemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit. Care Med. (2003) 31:1394-1398.
61. MOLOS M, HALL J: Symmetrical peripheral gangrene and disseminated intravascular coagulation. Arch. Dermatol. (1985) 121:1057-1061.
62. RODRIGUEZ-NUNEZ A, FERNANDEZ-SANMARTIN M, MARTINON-TOREZ F, GONZALES-ALONSO N, MARTINON-SANCHEZ J: Terlipressin for catecholamine resistant septic shock in children. Intensive Care Med. (2004) 30:477-480.
63. KHAN J, KRESS J, HALL J: Skin necrosis after extravasation of low dose vasopressin administered for septic shock. Crit. Care Med. (2002) 30:1899-1901.
64. GARCIA A, SANDOVAL J, AGUIRRE J, ELIZALDE J, FRANCO J, MARTINEZ J: Vasopressin infusion improves the hemodynamics in patients with septic shock (Abstract). Crit. Care Med. (2001) 29:A90.
65. DABBAGH O, AYOUB H, ALSHIRWAI N, ARABI Y, AL SHIMEMERI A: Use of vasopressin infusion as salvage therapy in septic patients on high dose catecholamines (Abstract). Chest (2003) 124:S224.
66. BRACCO D, CHIOLERO R, REVELLY J: Systemic and splanchnic haemodynamic effects of vasopressin administration in vasodilatory shock (Abstract). Intensive Care Med. (2001) 27:S138.
67. MANN H, BEILMAN G, BOM SONG J, HASINOFF I, LOHR B: Outcome of vasopressin treatment in vasodilatory septic shock (Abstract). Crit. Care Med. (2000) 28:A184.
68. GARCIA R, FRANCO J, AGUIRRE J, MARTINEZ J: Haemodynamic effects of early vasopressin infusion during septic shock (Abstract). Crit. Care Med. (2002) 30:A107.
69. ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY: Pitressin. In: ABN Compendium of data sheets and summaries of product characteristics. Walker G (Ed.), Datapharm Publications Ltd, London (1998-1999) p 946.
70. ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY Glypressin. In: ABPI Compendium of data sheets and summaries of product characteristics. Walker G (Ed.), Datapharm Publications Ltd, London (1998-1999):391.
71. British National Formulary. Mehta K (Ed.), British Medical Association and Royal Pharmaceutical Society of Great Britain, London (March 2005):379-381.
72. RIVERS E, NGUYEN B, HAVSTAD S et al.: Early goal directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. (2001) 345:1368-1377.
73. KLINZING S, SIMON M, REINHART K, BREDLE DL, MEIER-HELLMANN A: High-dose vasopressin is not superior to norepinephrine in septic shock. Crit. Care Med. (2003) 31:2646-2650.